References
- Aguilar OA, Qualls AE, Gonzalez-Hinojosa MDR et al (2024) MICB genomic variant is associated with NKG2D-mediated acute lung injury and death. Am J Respir Crit Care Med 209:70–82.
https://doi.org/10.1164/rccm.202303-0472OC - Baek IC, Shin DH, Choi EJ et al (2018) Association of MICA and MICB polymorphisms with the susceptibility of leukemia in Korean patients. Blood Cancer J 8:58.
https://doi.org/10.1038/s41408-018-0092-5 - Blunt MD, Khakoo SI (2023) Harnessing natural killer cell effector function against cancer. Immunother Adv 4:ltad031.
https://doi.org/10.1093/immadv/ltad031 - Bogunia-Kubik K, Łacina P (2021) Non-KIR NK cell receptors: Role in transplantation of allogeneic haematopoietic stem cells. Int J Immunogenet 48:157–171.
https://doi.org/10.1111/iji.12523 - Boutet P, Agüera-González S, Atkinson S et al (2009) Cutting edge: The metalloproteinase ADAM17/TNF-α-converting enzyme regulates proteolytic shedding of the MHC Class I-related chain B protein. J Immunol 182:49–53.
https://doi.org/10.4049/jimmunol.182.1.49 - Carapito R, Aouadi I, Pichot A et al (2020) Compatibility at amino acid position 98 of MICB reduces the incidence of graft-versus-host disease in conjunction with the CMV status. Bone Marrow Transplant 55:1367–1378.
https://doi.org/10.1038/s41409-020-0886-5 - Chitadze G, Bhat J, Lettau M et al (2013) Generation of soluble NKG2D ligands: Proteolytic cleavage, exosome secretion and functional implications. Scand J Immunol 78:120–129.
https://doi.org/10.1111/sji.12072 - Doubrovina ES, Doubrovin MM, Vider E et al (2003) Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J Immunol 171:6891–6899.
https://doi.org/10.4049/jimmunol.171.12.6891 - Eberhardt KA, Jung V, Knops E et al (2023) CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality. Bone Marrow Transplant 58:639–646.
https://doi.org/10.1038/s41409-023-01944-2 - Faridah IN, Dania H, Maliza R et al (2023) Genetic association studies of MICB and PLCE1 with severity of dengue in Indonesian and Taiwanese populations. Diagnostics 13:3365.
https://doi.org/10.3390/diagnostics13213365 - Farzad F, Yaghoubi N, Jabbari-Azad F et al (2022) Prognostic value of serum MICA levels as a marker of severity in COVID-19 patients. Immunol Invest 51:1856–1866.
https://doi.org/10.1080/08820139.2022.2069035 - Fuerst D, Neuchel C, Niederwieser D et al (2016) Matching for the MICA-129 polymorphism is beneficial in unrelated hematopoietic stem cell transplantation. Blood 128:3169–3176.
https://doi.org/10.1182/blood-2016-05-716357 - González-Cruz C, Repiso T, Ferrándiz-Pulido C et al (2023) Risk factors and clinical characteristics of acute and chronic cutaneous graft-versus-host disease in pediatric patients undergoing hematopoietic stem cell transplantation. Pediatr Dermatol 40:1077–1080.
https://doi.org/10.1111/pde.15447 - Goulding J, Yeh WI, Hancock B et al (2023) A chimeric antigen receptor uniquely recognizing MICA/B stress proteins provides an effective approach to target solid tumors. Med 4:457–477.e8.
https://doi.org/10.1016/j.medj.2023.04.004 - Groh V, Wu J, Yee C et al (2002) Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419:734–738.
https://doi.org/10.1038/nature01112 - Holdenrieder S, Stieber P, Peterfi A et al (2006a) Soluble MICA in malignant diseases. Int J Cancer 118:684–687.
https://doi.org/10.1002/ijc.21382 - Holdenrieder S, Stieber P, Peterfi A et al (2006b) Soluble MICB in malignant diseases: Analysis of diagnostic significance and correlation with soluble MICA. Cancer Immunol Immunother 55:1584–1589.
https://doi.org/10.1007/s00262-006-0167-1 - Holtick U, Quignot N, Kapso-Kapnang R et al (2024) Clinical and economic burden associated with acute graft-versus-host disease after allogeneic hematopoietic cell transplantation in Germany. Transplant Proc 56:191–200.
https://doi.org/10.1016/j.transproceed.2023.11.032 - Isernhagen A, Malzahn D, Viktorova E et al (2015) The MICA-129 dimorphism affects NKG2D signaling and outcome of hematopoietic stem cell transplantation. EMBO Mol Med 7:1480–1502.
https://doi.org/10.15252/emmm.201505246 - Ivanova M, Al Hadra B, Yordanov S et al (2021) Associations of high-resolution-typing-defined MICA and MICB polymorphisms, and the levels of soluble MICA and MICB with oral squamous cell carcinoma in Bulgarian patients. J Oral Pathol Med 50:758–765.
https://doi.org/10.1111/jop.13185 - Kaidun P, Holzmayer SJ, Greiner SM et al (2023) Targeting NKG2DL with bispecific NKG2D-CD16 and NKG2D-CD3 fusion proteins on triple-negative breast cancer. Int J Mol Sci 24:13156.
https://doi.org/10.3390/ijms241713156 - Kshersagar J, Damle MN, Bedge P et al (2022) Downregulation of MICA/B tumor surface expressions and augmented soluble MICA serum levels correlate with disease stage in breast cancer. Breast Dis 41:471–480.
https://doi.org/10.3233/BD-220023 - Machuldova A, Houdova L, Kratochvilova K et al (2021) Single-nucleotide polymorphisms in MICA and MICB genes could play a role in the outcome in AML patients after HSCT. J Clin Med 10:4636.
https://doi.org/10.3390/jcm10204636 - Nagai K, Tawara T, Usui J et al (2022) Levels of soluble NKG2D ligands and cancer history in patients starting hemodialysis. Front Nephrol 2:875207.
https://doi.org/10.3389/fneph.2022.875207 - Nuckel H, Switala M, Sellmann L et al (2010) The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia. Leukemia 24:1152–1159.
https://doi.org/10.1038/leu.2010.74 - Onyeaghala G, Nelson HH, Thyagarajan B et al (2017) Soluble MICA is elevated in pancreatic cancer: Results from a population based case-control study. Mol Carcinog 56:2158–2164.
https://doi.org/10.1002/mc.22667 - Ouni N, Ben Chaaben A, Ayari F et al (2020) MICA-129 Met/Val polymorphism could be a genetic biomarker for familial breast cancer in the Tunisian population. Int J Immunogenet 47:406–413.
https://doi.org/10.1111/iji.12480 - Ouni N, Ben Chaaben A, Kablouti G et al (2017) MICA-129Met/Val polymorphism is associated with early-onset breast cancer risk. Immunol Invest 46:603–614.
https://doi.org/10.1080/08820139.2017.1336175 - Parmar S, Del Lima M, Zou Y et al (2009) Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. Blood 114:2884–2887.
https://doi.org/10.1182/blood-2009-05-223172 - Passweg JR, Baldomero H, Ciceri F et al (2023) Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A report from the EBMT Activity Survey. Bone Marrow Transplant 58:647–658.
https://doi.org/10.1038/s41409-023-01943-3 - Patil S, Schwarer T (2009) Natural killer cells − new understanding of basic biology may lead to more effective allogeneic haematopoietic stem cell transplantation. Intern Med J 39:639–647.
https://doi.org/10.1111/j.1445-5994.2009.02024.x - Petersdorf EW, McKallor C, Malkki M et al (2023) Role of NKG2D ligands and receptor in haploidentical related donor hematopoietic cell transplantation. Blood Adv 7:2888–2896.
https://doi.org/10.1182/bloodadvances.2022008922 - Peterson EE, Barry KC (2021) The natural killer-dendritic cell immune axis in anti-cancer immunity and immunotherapy. Front Immunol 11:621254.
https://doi.org/10.3389/fimmu.2020.621254 - Prokopeva AE, Emene CC, Gomzikova MO (2023) Antitumor immunity: Role of NK cells and extracellular vesicles in cancer immunotherapy. Curr Issues Mol Biol 46:140–152.
https://doi.org/10.3390/cimb46010011 - Raffaghello L, Prigione I, Airoldi I et al (2004) Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 6:558–568.
https://doi.org/10.1593/neo.04316 - Ribeiro CH, Kramm K, Gálvez-Jirón F et al (2016) Clinical significance of tumor expression of major histocompatibility complex class I-related chains A and B (MICA/B) in gastric cancer patients. Oncol Rep 35:1309–1317.
https://doi.org/10.3892/or.2015.4510 - Salih HR, Goehlsdorf D, Steinle A (2006) Release of MICB molecules by tumor cells: Mechanism and soluble MICB in sera of cancer patients. Hum Immunol 67:188–195.
https://doi.org/10.1016/j.humimm.2006.02.008 - Sánchez-Cerrillo I, Calzada-Fraile D, Triguero-Martínez A et al (2023) MICa/b-dependent activation of natural killer cells by CD64+ inflammatory type 2 dendritic cells contributes to autoimmunity. EMBO J 42:e113714.
https://doi.org/10.15252/embj.2023113714 - Siemaszko J, Marzec-Przyszlak A, Bogunia-Kubik K (2021) NKG2D natural killer cell receptor-a short description and potential clinical applications. Cells 10:1420.
https://doi.org/10.3390/cells10061420 - Siemaszko J, Marzec-Przyszlak A, Bogunia-Kubik K (2023) Activating NKG2C receptor: Functional characteristics and current strategies in clinical applications. Arch Immunol Ther Exp 71:9.
https://doi.org/10.1007/s00005-023-00674-z - Spreu J, Stehle T, Steinle A (2006) Human cytomegalovirus-encoded UL16 discriminates MIC molecules by their α2 domains. J Immunol 177:3143–3149.
https://doi.org/10.4049/jimmunol.177.5.3143 - Sulaiman NY, Anuar NA, Arshad N et al (2024) CMV infection post allogeneic hematopoietic stem cell transplantation in a resource limited country. Indian J Hematol Blood Transfus 40:97–102.
https://doi.org/10.1007/s12288-023-01655-0 - Suresh PK (2016) Membrane-bound versus soluble major histocompatibility complex Class I-related chain A and major histocompatibility complex Class I-related chain B differential expression: Mechanisms of tumor eradication versus evasion and current drug development strategies. J Cancer Res Ther 12:1224–1233.
https://doi.org/10.4103/0973-1482.176169 - Vela-Ojeda J, Perez-Retiguin FDC, Olivas-Bejarano AC et al (2021) Clinical relevance of NKT cells and soluble MIC-A in Hodgkin lymphoma. Leuk Lymphoma 62:801–809.
https://doi.org/10.1080/10428194.2020.1852473 - Wang CM, Tan KP, Jan Wu YJ et al (2021) MICA*019 allele and soluble MICA as biomarkers for ankylosing spondylitis in Taiwanese. J Pers Med 11:564.
https://doi.org/10.3390/jpm11060564 - Wang LP, Niu H, Xia YF et al (2015) Prognostic significance of serum sMICA levels in non-small cell lung cancer. Eur Rev Med Pharmacol Sci 19:2226–2230
- Wang Y, Li S, Chen C et al (2019) MICB*002 and MICB*014 protect against rheumatoid arthritis, whereas MICA*009 and MICA*A6 are associated with rheumatoid arthritis in a Hainan Han Chinese population. Int J Rheum Dis 22:90–95.
https://doi.org/10.1111/1756-185X.13302 - Wu JD, Higgins LM, Steinle A et al (2004) Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 114:560–568.
https://doi.org/10.1172/JCI22206 - Xu Z, Taylor JA (2009) SNPinfo: Integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res 37(Web Server issue):W600-5.
https://doi.org/10.1093/nar/gkp290 - Yu P, Zhu Q, Chen C et al (2017) Association between major histocompatibility complex Class I chain-related gene polymorphisms and susceptibility of systemic lupus erythematosus. Am J Med Sci 354:430–435.
https://doi.org/10.1016/j.amjms.2017.06.003 - Zingoni A, Vulpis E, Cecere F et al (2018) MICA-129 dimorphism and soluble MICA are associated with the progression of multiple myeloma. Front Immunol 9:926.
https://doi.org/10.3389/fimmu.2018.00926 - Zocchi MR, Camodeca C, Nuti E et al (2015) ADAM10 new selective inhibitors reduce NKG2D ligand release sensitizing Hodgkin lymphoma cells to NKG2D-mediated killing. Oncoimmunology 5:e1123367.
https://doi.org/10.1080/2162402X.2015.1123367